Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects.

Time:2018-05-13 / View:642 times

Prev: In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis

Next: Concentration–response modeling of ECG data from early-phase clinical studies to assess QT prolongation risk of contezolid (MRX-I), an oxazolidinone antibacterial agent

Back